Advances in the use of biologic agents for the treatment of systemic vasculitis

Current Opinion in Rheumatology

Volumn 21, Issue 1, 2009, Pages 3-9

  Chung, Sharon A ^a   Seo, Philip ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Anti TNF; Intravenous immunoglobulin; Rituximab; Vasculitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; B CELL LYMPHOMA; CLINICAL TRIAL; CRYOGLOBULINEMIA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GIANT CELL ARTERITIS; HUMAN; INFECTION; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PSORIASIS; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC VASCULITIS; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 58149269251     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32831d28b3     Document Type: Review

References (60)

1. Cush J, Kavanaugh A. TNF-α blocking therapies, in Rheumatology. 4th ed. Hochberg M, editor. Philadelphia, PA: Mosby Elsevier; 2008. pp. 501-517.
2. Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001; 44:2933-2935.
3. Andonopoulos AP, Meimaris N, Daoussis D, et al. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003; 62:1116.
4. Airo P, Antonioli CM, Vianelli M, Toniati P. Antitumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002; 41:347-349.
5. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146:621 -630.
6. Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al. A double-blind • placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67:625-630. The first randomized trial investigating the use of etanercept in giant cell arteritis.
7. Ahmed MM, Mubashir E, Hayat S, et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007; 26:1353-1355.
8. Karageorgaki ZT, Mavragani CP, Papathanasiou MA, Skopouli FN. Infliximab in Takayasu arteritis: a safe alternative? Clin Rheumatol 2007; 26:984-987.
9. Delia Rossa A, Tavoni A, Merlini G, et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford) 2005; 44:1074-1075.
10. Jolly M, Curran JJ. Infliximab-responsive uveitis and vasculitis in a patient with Takayasu arteritis. J Clin Rheumatol 2005; 11:213-215.
11. Tanaka F, Kawakami A, Iwanaga N, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 2006; 45:313-316.
12. Tato F, Rieger J, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal antitumor necrosis factor antibody adalimumab. Int Angiol 2005; 24:304-307.
13. Hoffman GS, Merkel PA, Brasington RD, et al. Antitumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50:2296-2304.
14. Molloy ES, Langford CA, Clark TM, et al. Antitumor necrosis factor therapy in • patients with refractory Takayasu's arteritis: long-term follow-up. Ann Rheum Dis 2008; 67:1567-1569. The largest series to date describing the use of anti-TNF agents in Takayasu's arteritis.
15. Booth AD, Jefferson HJ, Ayliffe W, et al. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 2002; 61:559.
16. Josselin L, Mahr A, Cohen P, et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008; 67:1343-1346.
17. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss- Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002; 206:496-501.
18. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44:1149-1154.
19. Wilkinson NM, Erendzhinova E, Zeft A, Cabral DA. Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis. Rheumatology (Oxford) 2006; 45:1047-1048.
20. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-361.
21. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-2022.
22. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304-1312.
23. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088-1094.
24. Utz JP, Limper AH, Kakra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124:177-185.
25. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41:1303-1307.
26. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41:1126- 1132.
27. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717-721.
28. Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence? Clin Rev Allergy Immunol 2005; 29:237- 245.
29. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-673.
30. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003; (4): CD004000.
31. Asano Y, Ihn H, Maekawa T, et al. High-dose intravenous immunoglobulin infusion in polyarteritis nodosa: report on one case and review of the literature. Clin Rheumatol 2006; 25:396-398.
32. Hamidou MA, Pottier MA, Dupas B. Intravenous immunoglobulin in Henoch- Schonlein purpura. Ann Intern Med 1996; 125:1013-1014.
33. Jayne DR, Davies MJ, Fox CJ, et al. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337:1137-1139.
34. Tuso P, Moudgil A, Hay J, et al. Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin. Am J Kidney Dis 1992; 20:504-508.
35. Richter C, Schnabel A, Csernok E, et al. Treatment of Wegener's granulomatosis with intravenous immunoglobulin. Adv Exp Med Biol 1993; 336:487- 489.
36. Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996; 35:1150-1153.
37. Levy Y, Sherer Y, George J, et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999; 119:231-238.
38. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA- associated systemic vasculitis with persistent disease activity. QJM 2000; 93:433-439.
39. Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008; 58:308-317.
40. Bellisai F, Morozzi G, Marcolongo R, Galeazzi M. Pregnancy in Wegener's granulomatosis: successful treatment with intravenous immunoglobulin. Clin Rheumatol 2004; 23:533-535.
41. Masterson R, Pellicano R, Bleasel K, McMahon LP. Wegener's granulomatosis in pregnancy: a novel approach to management. Am J Kidney Dis 2004; 44:e68-e72.
42. Golbin JM, Specks U. Targeting B lymphocytes as therapy for ANCA- associated vasculitis. Rheum Dis Clin North Am 2007; 33:741 -754; v.
43. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359:613-626.
44. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-2581.
45. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146:25-33.
46. Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with peg- • interferon-ribavirin in refractory HCV-associated cryoglobulinemia vasculitis. Ann Rheum Dis 2008; 67:1431-1436. First report of using rituximab in combination with interferon and ribavrin for mixed cryoglobulinemia.
47. Cacoub P, Delluc A, Saadoun D, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? vAnn Rheum Dis 2008; 67:283-287.
48. Omdal R, Wildhagen K, Hansen T, et al. Anti-CD20 therapy of treatmentresistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005; 34:229-232.
49. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64:913-920.
50. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262-268.
51. Eriksson P. Nine patients with antineutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257:540-548.
52. Tamura N, Matsudaira R, Hirashima M, et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007;46:409-414.
53. Brihaye B, Aouba A, Pagnoux C, et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007; 25 (1 Suppl 44):S23-S27.
54. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008;35:2017-2023.
55. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180-187.
56. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65:853-858.
57. Stasi R, Stipa E, Del Poeta G, et al. Long-term observation of patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006; 45:1432-1436.
58. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54:2970-2982.
59. Ferraro AJ, Smith SW, Neil D, Savage CO. Relapsed Wegener's granulomatosis after rituximab therapy: B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood. Nephrol Dial Transplant 2008; 23:3030-3032.
60. US Food and Drug Administration. FDA alert: rituximab (marketed as Rituxan). December 2006; www.fda.gov/cder/drug/lnfoSheets/HCP/rituximab.pdf. [cited 8/1/2008]